TP53 mutations upregulate RCP expression via Sp1/3 to drive lung cancer progression.

导出原文传递

翻译打印收藏纠错

作者： Caihong,Wang ^[1] ; Shaosen,Zhang ^[2] ; Boyuan,Ma ^[3] ; Yan,Fu ^[4] ; Yongzhang,Luo ^[2]

作者单位： Beijing Institute of Tropical Medicine, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China. ^[1] School of Life Sciences, Tsinghua University, Beijing, 100084, China. ^[2] The National Engineering Research Center for Protein Technology, Tsinghua University, Beijing, 100084, China. ^[3] Beijing Key Laboratory for Protein Therapeutics, Tsinghua University, Beijing, 100084, China. ^[4] Department of Etiology and Carcinogenesis, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. ^[5] School of Life Sciences, Tsinghua University, Beijing, 100084, China. yluo@tsinghua.edu.cn. ^[6] The National Engineering Research Center for Protein Technology, Tsinghua University, Beijing, 100084, China. yluo@tsinghua.edu.cn. ^[7] Beijing Key Laboratory for Protein Therapeutics, Tsinghua University, Beijing, 100084, China. yluo@tsinghua.edu.cn. ^[8]

主题词人类(Humans);肺肿瘤(Lung Neoplasms);突变(Mutation);Sp1转录因子(Sp1 Transcription Factor);肿瘤抑制蛋白质p53(Tumor Suppressor Protein p53)

DOI 10.1038/s41388-022-02260-7

PMID 35256783

发布时间 2023-12-13

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交